Hosted on MSN
FDA Approves Johnson & Johnson’s TREMFYA for Pediatric Psoriasis and Psoriatic ArthritisHORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® (guselkumab) for children six years and older weighing at least 40 kilograms with ...
Pharmaceutical Technology on MSN
J&J’s Caplyta wins MDD approval to extend revenue horizon"J&J’s Caplyta wins MDD approval to extend revenue horizon" was originally created and published by Pharmaceutical Technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results